CMBA
ALXN

C.M. Bidwell & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

C.M. Bidwell & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-734
Closed -$135K – 639
2021
Q2 		$135K Buy
+734
New +$126K 0.09% 217
2020
Q1 		– Sell
-1,300
Closed -$141K – 493
2019
Q4 		$141K Sell
1,300
-1,980
-60% -$212K 0.13% 142
2019
Q3 		$321K Buy
3,280
+20
+0.6% +$2.25K 0.32% 91
2019
Q2 		$427K Sell
3,260
-3,570
-52% -$460K 0.42% 68
2019
Q1 		$923K Buy
6,830
+3,420
+100% +$425K 0.92% 15
2018
Q4 		$332K Buy
3,410
+3,160
+1,264% +$374K 0.36% 77
2018
Q3 		$35K Hold
250
– – 0.03% 256
2018
Q2 		$31K Buy
+250
New +$29.2K 0.03% 275

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return